Abstracts tagged "Systemic sclerosis"

Abstract Number: 2049 • ACR Convergence 2024
Genetically Proxied Glucose‑lowering Drug Target and Risk of Immune Mediated Inflammatory Disease: A Mendelian Randomization Study
Dongze Wu¹ and Yingzhao jin², ¹Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China (People's Republic), ²Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: There are conflicting findings on the relationship between glucose-lowering drugs and risk of development of immune mediated inflammatory diseases (IMIDs). The study aimed to…
Abstract Number: 2457 • ACR Convergence 2024
Polypharmacy, Drug-drug Interactions, and Adverse Drug Reactions Among Systemic Sclerosis Patients: A Cross-sectional Risk Factor Study
Sara Boukhlal¹, Laurent Chouchana², Malika Saadi³, marion Casadevall¹, Pascal cohen⁴, bertrand Dunogue⁵, Anne Murarasu¹, Alexis Régent⁶, Luc Mouthon⁵ and Benjamin Chaigne⁷, ¹AP HP, paris, France, ²Cochin, Paris, France, ³Cardiology Department - Cochin Hospital, Paris, France, ⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁷Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Polypharmacy, drug-drug interactions (DDI) and related adverse drug reaction (ADR) are understudied in SSc. The aim of this work was to determine the prevalence…
Abstract Number: 2683 • ACR Convergence 2024
Optical Coherence Angiography: A Non-invasive, Safe Method for Assessing the Systemic Sclerosis Related Vasculopathy Beyond Nailfold Capillaries
Pavel Nikitin¹, Harshdeep Chawla¹, Manmohan Singh¹, Samuel Theodore², Salavat Aglyamov¹, Meng Zhang², Brian Skaug², Maureen Mayes², Kirill Larin¹ and Shervin Assassi², ¹University of Houston, Houston, TX, ²UTHealth Houston Division of Rheumatology, Houston, TX
Background/Purpose: Vascular involvement is a prominent feature of systemic sclerosis (SSc). Safe and non-invasive methods to visualize cutaneous blood vessels beyond nailfold capillaries are lacking.…
Abstract Number: 0690 • ACR Convergence 2024
Can Immunosuppression or Vasodilation Prevent the Onset of Interstitial Lung Disease in Systemic Sclerosis? An Association Analysis from the EUSTAR Database
Liubov Petelytska¹, Lorenzo Tofani², Elise Siegert³, Elisabetta Zanatta⁴, Gianluca Moroncini⁵, Christina Bergmann⁶, vanessa smith⁷, Gabriela Riemekasten⁸, Kamal Solanki⁹, Fabio Cacciapaglia¹⁰, Britta Maurer¹¹, José da Silva¹², Marija Geroldinger-Simić¹³, Ana Rodrigues¹⁴, Madelon Vonk¹⁵, Jeska de Vries-Bouwstra¹⁶, Anna-Maria Hoffmann-Vold¹⁷, Oliver Distler¹⁸ and Cosimo Bruni¹⁹, and on behalf of the EUSTAR collaborators, ¹Bogomolets National Medical University, Kyiv, Kyyiv, Ukraine, ²University of Florence, Florence, Italy, ³Charité University Hospital, Berlin, Germany, ⁴Unit of Rheumatology, Padova University, Padova, Italy, ⁵Marche Polytechnic University, Ancona, Italy, ⁶Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁷Ghent University Hospital, Gent, Belgium, ⁸University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ⁹Waikato Hospital, Hamilton, New Zealand, ¹⁰Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ¹¹University Hospital Bern, University Bern, Bern, Switzerland, ¹²University of Coimbra, Coimbra, Portugal, ¹³Johannes Kepler University, Linz, Austria, ¹⁴Hospital Curry Cabral-Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal, ¹⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁶Leiden University Medical Center, Leiden, Netherlands, ¹⁷Oslo University Hospital, Oslo, Norway, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ¹⁹University of Zurich, Zurich, Switzerland
Background/Purpose: Inflammation and vasculopathy may play a role in the development of interstitial lung disease (ILD) in systemic sclerosis (SSc). Pre-clinical evidence showed possible preventive…
Abstract Number: 0951 • ACR Convergence 2024
A Feedback Loop Involving mtDNA, Platelets and Neutrophil Extracellular Traps Amplifies Inflammation in Systemic Sclerosis
Stavros Giaglis¹, Diego Kyburz² and Ulrich Walker³, ¹Experimental Rheumatology Laboratory, University of Basel, Basel, Switzerland, ²University Hospital Basel, Basel, Switzerland, ³Basel University Hospital, Basel, Switzerland
Background/Purpose: Mitochondria are essential eucaryotic cell organelles with several bacterial features, such as a double-stranded circular genome with hypomethylated CpG areas (1). A fundamental role of…
Abstract Number: 1070 • ACR Convergence 2024
Evaluating & Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients
John Hickernell¹ and Zineb Aouhab², ¹Loyola Univeristy Medical Center, Chicago, IL, ²Loyola University Medical Center, Oak Brook, IL
Background/Purpose: Annual screening for pulmonary hypertension (PH) in patients with Systemic Sclerosis (SSc) has been shown to decrease mortality. The American College of Radiology, European…
Abstract Number: 1577 • ACR Convergence 2024
Elevated Neutrophil Extracellular Traps in Systemic Sclerosis-associated Vasculopathy and Suppression by a Synthetic Prostacyclin Analog
Neda Kortam¹, Wenying Liang¹, Claire Shiple¹, Suiyuan Huang¹, Rosemary Gedert¹, James St. Clair¹, Cyrus Sarosh², Caroline Foster¹, Eliza Pei-Suen Tsou¹, John Varga¹, Jason Knight¹, Dinesh Khanna¹ and Ramadan Ali¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI
Background/Purpose: Neutrophils and neutrophil extracellular traps (NETs) contribute to the vascular complications of multiple diseases, but their role in systemic sclerosis (SSc) is understudied. We…
Abstract Number: 1817 • ACR Convergence 2024
Activated Macrophages Mediate Loss of Dermal White Adipose Tissue in Fibrotic Skin
Chanhyuk Park¹, Helen Jarnagin², Asmaa Mohamed³, Yina Huang³, Michael Whitfield⁴ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Dartmouth, Lebanon, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Autoimmune systemic sclerosis (SSc) is characterized by inflammation, vasculopathy, and dermal and internal organ fibrosis. A widely-reported but poorly understood aspect of SSc skin…
Abstract Number: 2183 • ACR Convergence 2024
Accuracy of AI Tools for Diagnosis of Connective Tissue Disease
Indira Sriram¹, Gabriel Tarshish² and Megan Curran², ¹University of Colorado, Aurora, CO, ²Children's Hospital Colorado, Aurora, CO
Background/Purpose: In this work, we study the ability of generative artificial intelligence (AI) based tools to diagnose pediatric rheumatological diseases. Specifically, we seek to answer…
Abstract Number: 2458 • ACR Convergence 2024
Risk Factors for Progression of Interstitial Lung Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis
Julie Urgiles¹, Suiyuan Huang², Shervin Assassi³, Flavia Castelino⁴, Robyn Domsic⁵, Tracy Frech⁶, Jessica Gordon⁷, Faye Hant⁸, Monique Hinchcliff⁹, Ami Shah¹⁰, Victoria Shanmugam¹¹, Virginia Steen¹², Dinesh Khanna² and Elana Bernstein¹³, ¹Columbia University Irving Medical Center, New York, NY, ²University of Michigan, Ann Arbor, MI, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴Massachusetts General Hospital, Boston, MA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁶Vanderbilt University Medical Center, Nashville, TN, ⁷Division of Rheumatology, Weill Cornell Medical College, New York, NY, ⁸Medical University of South Carolina, Charleston, SC, ⁹Yale School of Medicine, Westport, CT, ¹⁰Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ¹¹Office of Autoimmune Disease Research, Office of Research on Women's Health, National Institutes of Health, Great Falls, VA, ¹²Georgetown University School of Medicine, Washington, DC, ¹³Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY
Background/Purpose: Interstitial lung disease (ILD) is one of the main pulmonary complications of systemic sclerosis (SSc), with a prevalence of 50-60%. SSc-ILD progression can occur…
Abstract Number: 2686 • ACR Convergence 2024
Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells
David Fox¹, Laura Cooney², Lia Stelzig³, Robert Lafyatis⁴, Johann Gudjonsson⁵, Lam Tsoi⁶, Maureen Mayes⁷, Ankoor Shah⁸, Suzanne Kafaja⁹, William Barry³, Ellen Goldmuntz¹⁰, Dawn Smilek¹¹ and Dinesh Khanna⁶, ¹University of Michigan, Dexter, MI, ²University of Michigan and Immune Tolerance Network, Ann Arbor, MI, ³Rho, Durham, NC, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI, ⁶University of Michigan, Ann Arbor, MI, ⁷UTHealth Houston Division of Rheumatology, Houston, TX, ⁸Duke University, Durham, NC, ⁹Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ¹⁰Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, ¹¹Immune Tolerance Network, UCSF, San Francisco, CA
Background/Purpose: Brentuximab vedotin (ADCETRIS®) is a drug antibody conjugate targeting CD30 approved for treatment of Hodgkin’s lymphoma (HL) and other hematologic malignancies. Association of CD30…
Abstract Number: 0691 • ACR Convergence 2024
Predictors of Response and Long-term Efficacy and Safety of Nintedanib in Systemic Sclerosis-Interstitial Lung Disease: Data from an Italian Multicentre Study
Corrado Campochiaro¹, Giacomo De Luca², Maria-Grazia Lazzaroni³, Giuseppe Armentaro⁴, Amelia Spinella⁵, Chiara Bellocchi⁶, Barbara Ruaro⁷, Anna Stanziola⁸, Devis Benfaremo⁹, Enrico De Lorenzis¹⁰, Beatrice Moccaldi¹¹, Francesco Bonomi¹², Lorenzo Bianchessi¹³, Florenzo Iannone¹⁴, Fabio Cacciapaglia¹⁵, Lorenzo Beretta¹⁶, Serena Guiducci¹⁷, Veronica Codullo¹⁸, Silvia Laura Bosello¹⁹, Giovanna Cuomo²⁰, Elisabetta Zanatta¹¹, Nicoletta Del Papa⁴, Paolo Airò³, paola Confalonieri⁷, Gianluca Moroncini⁹, Dilia Giuggioli⁵, Lorenzo Dagna²¹ and Marco Matucci-Cerinic²², ¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ³Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ⁴Scleroderma Clinic, Dip. Reumatologia, ASST G. Pini-CTO, Milan, Italy, ⁵Scleroderma Unit, University of Modena and Reggio Emilia, Modena, Italy, ⁶Università degli Studi di Milano, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, ⁷Unit of Respiratory Medicine, University of Trieste, Trieste, Italy, ⁸Unit of Respiratory Medicine, Federico II University Hospital, Napoli, Italy, ⁹Department of Clinical and Molecular Sciences, Marche Polytechnic University & Department of Internal Medicine, Marche University Hospital, Ancona, Italy, ¹⁰Catholic University of the Sacred Heart, Roma, Rome, Italy, ¹¹Unit of Rheumatology, Padova University, Padova, Italy, ¹²Azienda Ospedaliera Universitaria Careggi, Florence, Florence, Italy, ¹³Unit of Rheumatology, San Matteo Hospital, Pavia, ¹⁴Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ¹⁵Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ¹⁶Scleroderma Unit, Fondazione IRCCS Ca' Granda, University of Milan, Milan, Italy, ¹⁷Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁸Unit of Rheumatology, San Matteo Hospital, Pavia, Italy, ¹⁹Unit of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²⁰Università degli studi della Campania Luigi Vanvitelli, Napoli, Italy, ²¹IRCCS San Raffaele Scientific Institute, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milano, Italy, Milan, Italy, ²²University San Raffaele Milano, Milano, Milan, Italy
Background/Purpose: The SENSCIS trial and the SENSCIS-ON study have shown that nintedanib (NTD) reduces the rate of decline in Interstitial Lung Disease (ILD) in Systemic…
Abstract Number: 0952 • ACR Convergence 2024
Single Cell RNA-seq of Scleroderma-associated Interstitial Lung Disease Lung Explants Reveals an Active, Cytotoxic Natural Killer Cell Population
Cristina Padilla, Eleanor Valenzi, Tracy Tabib, Banafsheh Nazari, Patrizia Fuschiotti and Robert Lafyatis, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Scleroderma-associated interstitial lung disease (SSc-ILD) is the leading cause of death among SSc patients. Loss of alveolar epithelial cells (AEC) and bronchial cell hyperplasia,…
Abstract Number: 1130 • ACR Convergence 2024
Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease
Melanie Hagen¹, Laura Bucci¹, Sebastian Boeltz², Danae-Mona Noethling², Tobias Rothe², Maria Gabriella Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Aline Bozec¹, Georg Schett³ and Ricardo Grieshaber-Bouyer¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: B-cells and plasma cells are key drivers of systemic autoimmune diseases (AID). Recent data demonstrated preliminary safety and efficacy of using the CD3xCD19 bispecific…
Abstract Number: 1578 • ACR Convergence 2024
Association of Systemic Sclerosis and Other Systemic Autoimmune Disease Diagnosis with Increasing Anti-RNA Polymerase III Antibodies
Warren Balaja¹, Mashood Badshah² and Megan Krause³, ¹University of Kansas Medical Center, Kansas City, KS, ²The University of Kansas Medical Center, Kansas City, KS, ³University of Kansas, Kansas City, KS
Background/Purpose: Anti-RNA polymerase III antibody (ARA) is a disease-specific antibody important for the identification and stratification of varying phenotypes of systemic sclerosis (SSc). Previous studies…

« Previous Page
1
…
6
7
8
9
10
…
46
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].